THERAVANCE WKN: A2AC9U ISIN: US45781M1018 Kürzel: HVE Forum: Aktien Thema: Hauptdiskussion

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the treatment of uncomplicated urogenital gonorrhea. Positive study results are a significant milestone in the development of a first-in-class single-dose, oral antibiotic against gonorrhea, including infections caused by drug-resistant Neisseria gonorrhoeae, an urgent public health threat and high-priority pathogen. Gonorrhea is the second most reported bacterial STI in the United States, with resistance to first-line treatment emerging.1,2